PDS Biotechnology Appoints Kamil Ali-Jackson, Esq. to Board of Directors
February 24 2020 - 7:30AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immuno-oncology company developing multiple therapies based on the
Company’s proprietary Versamune® T-cell activating technology,
today announced that it has appointed Kamil Ali-Jackson, Esq. to
its Board of Directors. Ms. Ali-Jackson will be a member of the
Board’s audit committee.
“We are very pleased to welcome Kamil to the
Board of Directors and look forward to her insights and
contributions as we continue to progress the company’s
Versamune®-based clinical and preclinical pipeline and grow PDS
into a leading immuno-oncology company. Kamil’s extensive legal
experience, particularly with financial transactions, strategic
alliances, and development and commercialization transactions, will
be an invaluable asset to the team and help guide the Company,”
commented Steve Glover, Chairman of the Board of PDS. “With our
successful financing complete we look forward to initiating three
Phase 2 clinical trials for our lead product candidate PDS0101 over
the coming months.”
Kamil Ali-Jackson, Esq. has more than 30 years
of experience as legal counsel in the life sciences industry with
public and private specialty pharmaceutical, biotech and
biopharmaceutical companies. Ms. Ali-Jackson has extensive domestic
and international experience with strategic alliances, drug
development and commercialization collaborations and M&A
transactions. She is a co-founder of Aclaris Therapeutics, Inc. and
has served as Chief Legal Officer since its inception in 2012. In
addition, since 2013, she has served as Chief Legal Officer of
NeXeption II, LLC and its affiliates. Previously, Kamil served as
Chief Legal Officer of Ralexar Therapeutics, Inc. (formerly known
as Alexar Therapeutics Inc.). She has also served as legal counsel
and as a licensing business executive for large pharmaceutical
companies, including Merck & Co. Inc., Dr. Reddy’s Laboratories
Ltd., and Endo Pharmaceuticals, Inc.
Ms. Ali-Jackson holds her Juris Doctorate from
Harvard Law School in addition to a Bachelor of Arts degree in
politics from Princeton University. She was a 2011 Philadelphia
Business Journal Woman of Distinction winner. She has served on
several nonprofit boards and is currently on the board of Rosemont
College, a private liberal arts college located in
Pennsylvania.
About PDS Biotechnology
PDS Biotech is a clinical-stage immuno-oncology
company developing multiple therapies based on the Company’s
proprietary Versamune® T-cell activating technology platform. The
Versamune® platform effectively delivers tumor-specific antigens
for in vivo uptake and processing, while also activating a critical
immunological pathway, the type 1 interferon pathway, thus
resulting in the production of potent tumor-specific killer
T-cells. Using Versamune®, PDS Biotech is engineering therapies
designed to better recognize cancer cells and break down their
defense systems to effectively attack and destroy tumors. PDS
Biotech’s pipeline combines the Versamune® technology with
tumor-specific antigens across several cancer types. To learn more,
please visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
About PDS0101
PDS Biotech’s lead candidate, PDS0101, combines
the utility of the Versamune® platform with targeted antigens in
HPV-expressing cancers. In partnership with Merck, PDS Biotech is
advancing a combination of PDS0101 and KEYTRUDA® to a Phase 2 study
in first line treatment of recurrent or metastatic head and neck
cancer. In partnership with the National Cancer Institute (NCI),
PDS Biotech is also advancing a combination of PDS0101 and two
clinical stage immunotherapies to a Phase 2 study in advanced
HPV-associated cancers. A third phase 2 study is to be performed in
advanced localized cervical cancer combining PDS0101 with the
chemoradiotherapy, which is the standard of care.
Forward Looking StatementsThis
communication contains forward-looking statements (including within
the meaning of Section 21E of the United States Securities Exchange
Act of 1934, as amended, and Section 27A of the United States
Securities Act of 1933, as amended) concerning PDS Biotechnology
Corporation (the “Company”) and other matters. These statements may
discuss goals, intentions and expectations as to future plans,
trends, events, results of operations or financial condition, or
otherwise, based on current beliefs of the Company’s management, as
well as assumptions made by, and information currently available
to, management. Forward-looking statements generally include
statements that are predictive in nature and depend upon or refer
to future events or conditions, and include words such as “may,”
“will,” “should,” “would,” “expect,” “anticipate,” “plan,”
“likely,” “believe,” “estimate,” “project,” “intend,” and
other similar expressions among others. Statements that are not
historical facts are forward-looking statements. Forward-looking
statements are based on current beliefs and assumptions that are
subject to risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
contained in any forward-looking statement as a result of various
factors, including, without limitation: the ability of the Company
to integrate Edge and PDS Biotechnology following the merger; the
Company’s ability to protect its intellectual property rights;
competitive responses to the completion of the merger; potential
adverse reactions or changes to business relationships resulting
from the completion of the merger; the Company’s anticipated
capital requirements, including the Company’s anticipated cash
runway and the Company’s current expectations regarding its plans
for future equity financings; the timing for the Company or its
partners to initiate the planned clinical trials for its lead
assets, PDS0101 and PDS0102; the Company’s interpretation of the
results of its Phase 1 trial for PDS0101 and whether such results
are sufficient to support additional trials or the future success
of such trials; the successful implementation of the Company’s
research and development programs and collaborations, including any
collaboration studies concerning PDS0101 and the Company’s
interpretation of the results and findings of such programs and
collaborations and whether such results are sufficient to support
the future success of the Company’s product candidates; the
acceptance by the market of the Company’s product candidates, if
approved; the timing of and the Company’s ability to obtain
and maintain U.S. Food and Drug Administration or other
regulatory authority approval of, or other action with respect to,
the Company’s product candidates; and other factors, including
legislative, regulatory, political and economic
developments not within the Company’s control. The foregoing
review of important factors that could cause actual events to
differ from expectations should not be construed as exhaustive and
should be read in conjunction with statements that are included
herein and elsewhere, including the risk factors included in the
Company’s annual and periodic reports filed with the SEC. The
forward-looking statements are made only as of the date of this
press release and, except as required by applicable law, the
Company undertakes no obligation to revise or update any
forward-looking statement, or to make any other forward-looking
statements, whether as a result of new information, future events
or otherwise.
Media & Investor Relations
Contact:
Deanne RandolphPDS BiotechPhone: +1 (908)
517-3613Email: drandolph@pdsbiotech.com
Tram Bui / Alexander LoboThe Ruth GroupPhone: +1
(646) 536-7035 / +1 (646) 536-7037Email: tbui@theruthgroup.com /
alobo@theruthgroup.com
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2024 to Oct 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Oct 2023 to Oct 2024